Novus Acquisition & Development Corp.
NDEV
Other OTC0.02
USD
+0.00
- -
ISIN
US67011R2058
CUSIP
67011R205
Return %
Stock
S&P500
1Y
-60.77
26.53
3Y
-27.14
76.60
5Y
-76.35
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Gary Frank Labrozzi
- Full Time Employees
- 1
- Sector
- Financial Services
- Industry
- Insurance - Diversified
- Address
- 2665 South Bayshore Drive Miami FL United States of America 33131
- IPO Date
- Jan 9, 2013
- Website
- getnovusnow.com
- Similar Companies
- Business
- Novus Acquisition & Development Corp. Novus Acquisition & Development Corp. (NDEV), founded in 1996 and headquartered in Miami, Florida, operates as a health insurance carrier specializing in supplemental plans that integrate cannabis benefits for medical and recreational users across the United States. Through its wholly owned subsidiary WCIG Insurance Services, Inc., the company offers proprietary health policies focused on THC and CBD cannabis coverage; benefit plans including dental, vision, hearing, and telemedicine services; discounted medical plans for alternative medicine treatments; and a nationwide network of over 1,200 agents, brokers, and licensed dispensaries that provide policyholders with preferred rates on cannabis medications and delivery options. Novus generates revenue primarily through insurance premiums via a receivable-based business model, targeting chronic condition patients, unregistered consumers from the illicit market, recreational users, and employers seeking customizable wellness programs compliant with Health Savings Accounts and Health Reimbursement Accounts. The company maintains a non-plant-touching structure, enabling operations on a state-by-state basis unaffected by federal cannabis banking or rescheduling issues, while serving diverse customer segments in the wellness, medical marijuana, and insurtech industries. In recent developments, Novus launched a direct-to-consumer Cannabis RX online platform in early 2025, merging a 20,000-item prescription drug formulary with cannabis benefits for dual-coverage solutions, pre-negotiated discounts, and nationwide dispensary access; expanded market efforts through partnerships with dispensaries, cannabis brands, and brokers to penetrate employer markets adjusting cannabis HR policies; and reported steady Q2 2025 financial performance with strategic provider enrollment acceleration, underscoring organic growth in cannabis-inclusive plans as evidenced by its 10-K filing for 2024 and ongoing investor outreach.
Novus Releases 2Q Results, Underscores Independent Organic Growth In Cannabis
Branded Legacy and Novus Partner to Develop Plant-Based Meds for Health Plans